Skip to main content
. 2019 Feb 18;5(1):e000798. doi: 10.1136/rmdopen-2018-000798

Figure 2.

Figure 2

Evidence base networks for American College of Rheumatology 20 outcomes at 24 weeks. Comi, combination; csDMARD, conventional synthetic disease-modifying antirheumatic drugs; IR, inadequate responders; MTX, methotrexate; TNFi, tumour necrosis factor α inhibitors.